Benjamin Besse
#121,589
Most Influential Person Now
Researcher
Benjamin Besse's AcademicInfluence.com Rankings
Benjamin Bessecomputer-science Degrees
Computer Science
#4931
World Rank
#5208
Historical Rank
Machine Learning
#1127
World Rank
#1146
Historical Rank
Artificial Intelligence
#1357
World Rank
#1384
Historical Rank
Database
#2104
World Rank
#2213
Historical Rank
Download Badge
Computer Science
Benjamin Besse's Degrees
- PhD Computer Science Université Paris Cité
- Bachelors Computer Science Université Paris Cité
Similar Degrees You Can Earn
Why Is Benjamin Besse Influential?
(Suggest an Edit or Addition)Benjamin Besse's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) (3079)
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer (2012) (1151)
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. (2016) (768)
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) (2016) (740)
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. (2019) (711)
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019) (627)
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. (2018) (595)
- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. (2016) (575)
- Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. (2013) (567)
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy (2018) (529)
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer (2018) (508)
- Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC (2015) (473)
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. (2018) (451)
- CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients (2015) (412)
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. (2017) (411)
- A Genomics-Based Classification of Human Lung Tumors (2013) (403)
- Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. (2010) (402)
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation. (2021) (393)
- Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. (2015) (318)
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. (2020) (297)
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. (2013) (286)
- Hyperprogressive disease: recognizing a novel pattern to improve patient management (2018) (277)
- Caring for patients with cancer in the COVID-19 era (2020) (274)
- The evolving role of histology in the management of advanced non-small-cell lung cancer. (2010) (270)
- Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. (2013) (270)
- Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. (2014) (266)
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. (2017) (259)
- Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report (2020) (257)
- Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. (2016) (246)
- Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. (2004) (241)
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. (2018) (232)
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. (2014) (223)
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? (2018) (219)
- Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer (2014) (217)
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas (2015) (217)
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. (2019) (209)
- Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. (2010) (208)
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. (2018) (205)
- Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment (2017) (188)
- Bevacizumab Safety in Patients with Central Nervous System Metastases (2009) (186)
- Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study (2015) (185)
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer (2019) (183)
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. (2019) (170)
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study (2019) (159)
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (2020) (158)
- Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA (2017) (152)
- Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
- Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. (2019) (145)
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. (2019) (144)
- Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. (2019) (143)
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort (2015) (140)
- Lung cancer in never-smokers (2015) (138)
- Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. (2018) (132)
- Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. (2017) (126)
- Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study (2017) (125)
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer (2019) (125)
- Cutaneous side‐effects in patients on long‐term treatment with epidermal growth factor receptor inhibitors (2009) (121)
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. (2021) (118)
- Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. (2007) (115)
- Prognostic impact of vitamin B6 metabolism in lung cancer. (2012) (114)
- Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. (2017) (113)
- Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? (2017) (111)
- High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer (2015) (109)
- Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers (2016) (108)
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. (2018) (102)
- Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites (2009) (97)
- Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers (2018) (94)
- Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort (2020) (94)
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (91)
- From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF) (2012) (91)
- Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) (91)
- Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors (2019) (87)
- Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). (2019) (87)
- Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (2016) (85)
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC (2014) (85)
- A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung (2010) (84)
- Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer (2019) (84)
- ERCC1 and RRM1: ready for prime time? (2013) (83)
- The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. (2017) (81)
- Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression (2021) (81)
- New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response (2014) (78)
- LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. (2017) (78)
- 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) (2015) (75)
- Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. (2012) (72)
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers (2019) (71)
- Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer (2019) (70)
- Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. (2005) (69)
- A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups (2017) (68)
- Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer (2014) (68)
- 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC (2016) (67)
- Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. (2014) (67)
- Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. (2018) (66)
- Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. (2013) (64)
- Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. (2018) (64)
- Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. (2018) (63)
- KRAS oncogene in lung cancer: focus on molecularly driven clinical trials (2016) (62)
- Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. (2007) (61)
- PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) (2012) (61)
- Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC (2011) (61)
- Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. (2017) (61)
- Integrated molecular portrait of non-small cell lung cancers (2013) (60)
- Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? (2017) (60)
- Circulating Tumor Cells in Lung Cancer (2012) (60)
- EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. (2020) (59)
- Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study (2018) (59)
- Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. (2020) (59)
- Are liquid biopsies a surrogate for tissue EGFR testing? (2018) (58)
- Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer (2011) (57)
- Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. (2014) (56)
- Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. (2022) (55)
- Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC (2015) (55)
- Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. (2009) (55)
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). (2020) (55)
- Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France (2017) (55)
- Tumour burden and efficacy of immune-checkpoint inhibitors (2021) (54)
- Do immune checkpoint inhibitors need new studies methodology? (2018) (54)
- EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. (2019) (52)
- Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). (2012) (52)
- Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. (2011) (52)
- Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer (2017) (51)
- Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy (2020) (51)
- Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial (2017) (51)
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial (2020) (50)
- Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. (2017) (50)
- Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment (2018) (49)
- Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort (2018) (48)
- Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. (2018) (48)
- Progress in the Management of Advanced Thoracic Malignancies in 2017 (2018) (47)
- Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. (2015) (47)
- Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma. (2011) (45)
- Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007) (2012) (45)
- CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17 (2020) (44)
- Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
- Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. (2021) (44)
- Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. (2019) (43)
- Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. (2018) (42)
- Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non–Small Cell Lung Cancer (2007) (42)
- Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm (2020) (42)
- Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. (2016) (42)
- Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. (2019) (41)
- VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study (2022) (40)
- Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. (2020) (40)
- Thymic carcinomas: clinicopathologic study of 37 cases from a single institution (2013) (40)
- Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. (2020) (40)
- Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? (2014) (40)
- Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? (2018) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II (2015) (39)
- Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? (2010) (39)
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial (2021) (39)
- Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL (2011) (38)
- Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments (2020) (38)
- Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) (2007) (37)
- LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY (2014) (37)
- Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. (2019) (37)
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. (2022) (37)
- Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology (2013) (36)
- OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer (2017) (36)
- Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial (2018) (35)
- MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study (2017) (35)
- Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression. (2019) (35)
- Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. (2017) (34)
- Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC (2016) (34)
- Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer (2017) (34)
- Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation? (2019) (34)
- Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program (2017) (33)
- OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2017) (32)
- Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. (2020) (32)
- Small cell lung cancer: a slightly less orphan disease after immunotherapy. (2021) (32)
- Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer (2019) (32)
- An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer (2013) (32)
- Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. (2020) (32)
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (2014) (31)
- Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. (2012) (31)
- Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. (2005) (31)
- Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis. (2021) (30)
- Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer (2017) (30)
- EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR (2018) (29)
- Nuclear Localization of Apoptosis Protease Activating Factor-1 Predicts Survival after Tumor Resection in Early-Stage Non–Small Cell Lung Cancer (2004) (29)
- A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. (2014) (29)
- Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? (2019) (29)
- New windows open for immunotherapy in lung cancer (2018) (29)
- Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer. (2019) (29)
- Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? (2019) (28)
- Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. (2017) (28)
- Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy (2020) (27)
- QT interval prolongation among patients treated with angiogenesis inhibitors (2009) (27)
- Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study. (2017) (27)
- Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer (2016) (27)
- Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities (2015) (27)
- Method for semi-automated microscopy of filtration-enriched circulating tumor cells (2016) (27)
- Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE. (2016) (27)
- EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. (2019) (27)
- MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC (2018) (27)
- LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. (2014) (26)
- Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer (2018) (26)
- OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer (2018) (26)
- Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. (2010) (26)
- Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. (2015) (26)
- Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort (2017) (25)
- Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. (2019) (25)
- Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) (2020) (25)
- EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice (2017) (25)
- Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. (2019) (25)
- Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma (2012) (25)
- Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. (2021) (25)
- 1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO) (2017) (25)
- The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. (2020) (24)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. (2014) (24)
- Second-line combination therapies in nonsmall cell lung cancer without known driver mutations (2015) (24)
- A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). (2011) (24)
- MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer. (2021) (24)
- Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (23)
- Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers (2008) (23)
- Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1 (2019) (23)
- Targeted therapies in lung cancer. (2007) (23)
- An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). (2016) (23)
- Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). (2012) (23)
- A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial (2020) (22)
- Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. (2021) (22)
- The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. (2009) (22)
- The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer (2015) (22)
- Therapeutic management of ALK+ nonsmall cell lung cancer patients (2015) (22)
- Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer (2019) (22)
- A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (2015) (22)
- A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). (2014) (21)
- Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis (2021) (21)
- Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. (2018) (21)
- A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. (2017) (21)
- OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study (2017) (21)
- Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. (2018) (20)
- Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. (2008) (20)
- A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib (2016) (20)
- The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy (2012) (20)
- Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer (2020) (20)
- Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. (2015) (20)
- Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. (2021) (19)
- ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD‐L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology (2016) (19)
- Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases (2019) (19)
- CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). (2020) (19)
- A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer. (2021) (19)
- Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours (2018) (19)
- [Prognostic and predictive factors in lung cancer]. (2009) (19)
- Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? (2008) (18)
- Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). (2020) (18)
- EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. (2017) (18)
- Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression (2020) (18)
- Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. (2018) (17)
- Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations (2018) (17)
- LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer (2020) (17)
- Developments in the treatment of early NSCLC: when to use chemotherapy. (2012) (17)
- High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome (2020) (17)
- Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. (2019) (17)
- A Randomized, Placebo‐Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum‐Based Chemotherapy as First‐Line Treatment for Extensive‐Stage Small‐Cell Lung Cancer (2017) (17)
- A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial. (2020) (17)
- Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. (2018) (17)
- Prognostic value of LIPC in non-small cell lung carcinoma (2013) (17)
- Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. (2021) (17)
- Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN). (2013) (16)
- IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment (2020) (16)
- Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM) (2016) (16)
- Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation (2017) (16)
- Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial (2022) (16)
- MA07.11 Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC) (2017) (16)
- Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade (2021) (16)
- Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial (2022) (16)
- Surgical management of thymic epithelial tumors in children: Lessons from the French Society of pediatric oncology and review of the literature (2014) (16)
- Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007. (2016) (16)
- 203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer (2008) (16)
- Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy (2020) (16)
- Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer (2013) (15)
- The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. (2016) (15)
- Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated (2019) (15)
- Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. (2011) (15)
- Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice (2009) (15)
- Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. (2020) (15)
- Whole brain radiotherapy in patients with NSCLC and brain metastases (2016) (14)
- Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. (2022) (14)
- Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study (2007) (14)
- Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? (2014) (14)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study. (2020) (14)
- Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (2008) (14)
- Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (14)
- Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. (2019) (14)
- Hypokalemia, metabolic alkalosis, and hypertension in a lung cancer patient. (2009) (14)
- Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC) (2016) (13)
- Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study (2017) (13)
- ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. (2011) (13)
- Proposals for managing patients with thoracic malignancies during COVID-19 pandemic (2020) (13)
- Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. (2015) (13)
- EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). (2016) (13)
- 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial (2020) (13)
- Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer (2020) (13)
- Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup. (2013) (13)
- Radon and Lung Cancer: Current Trends and Future Perspectives (2022) (13)
- Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. (2015) (13)
- Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial (2017) (13)
- P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100 (2021) (13)
- Is sacrifying the phrenic nerve during thymoma resection worthwhile? (2014) (13)
- Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib (2012) (13)
- Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. (2019) (12)
- Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO). (2019) (12)
- Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors (2021) (12)
- Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. (2010) (12)
- Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study. (2018) (12)
- 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2 (2021) (12)
- Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer (2020) (12)
- 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation (2020) (12)
- AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC). (2020) (12)
- Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. (2016) (12)
- Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial (2020) (12)
- Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer. (2021) (12)
- Thymic Epithelial Tumor‐Associated Cytopenia: A 10‐Year Observational Study in France (2016) (12)
- Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy? (2019) (11)
- Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. (2015) (11)
- Synaptic Release of CCL5 Storage Vesicles Triggers CXCR4 Surface Expression Promoting CTL Migration in Response to CXCL12 (2014) (11)
- Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. (2022) (11)
- P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC: Topic: IT (2017) (11)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (2019) (11)
- Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay (2020) (11)
- Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. (2018) (11)
- 1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP) (2017) (11)
- Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations (2021) (11)
- Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. (2017) (11)
- Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies (2022) (11)
- PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. (2021) (11)
- Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. (2015) (11)
- Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report (2020) (11)
- Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. (2019) (11)
- P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (2017) (10)
- Hyperprogression during immunotherapy: do we really want to know? (2019) (10)
- One or Two Immune Checkpoint Inhibitors? (2019) (10)
- Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC). (2016) (10)
- The promise of pharmacogenomics: gemcitabine and pemetrexed. (2004) (10)
- Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). (2019) (10)
- Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC) (2020) (10)
- 7114 Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis (2009) (10)
- 1323PBaseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (2017) (10)
- Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (2020) (10)
- Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. (2022) (10)
- Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases. (2020) (10)
- Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. (2020) (10)
- [Targeted therapies in non-small cell lung cancer in 2014]. (2015) (9)
- [Systemic treatment of brain metastases from lung cancer]. (2015) (9)
- Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. (2014) (9)
- Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). (2018) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- Hyperprogression during immunotherapy: do we really want to know? (2019) (9)
- Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC). (2021) (9)
- Author Correction: Caring for patients with cancer in the COVID-19 era (2020) (9)
- Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients (2017) (9)
- CD8CD103 Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients (2015) (9)
- Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial. (2021) (9)
- A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. (2017) (9)
- 543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 (2020) (9)
- Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM). (2022) (8)
- ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. (2012) (8)
- Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma (2020) (8)
- Abstract CT131: Entrectinib inNTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001) (2019) (8)
- Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial (2020) (8)
- Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (2020) (8)
- Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients (2019) (8)
- OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS (2021) (8)
- Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. (2021) (8)
- Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. (2020) (8)
- Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer (2016) (8)
- 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts) (2020) (8)
- Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001. (2022) (8)
- MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts (2018) (8)
- P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients (2018) (8)
- 3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC) (2015) (8)
- Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (2019) (8)
- MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation (2021) (8)
- Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study (2021) (8)
- EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. (2022) (8)
- [Rythmic-pathology: the French national pathology network for thymic epithelial tumours]. (2014) (8)
- Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply. (2019) (7)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration. (2019) (7)
- Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors? (2019) (7)
- Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer. (2009) (7)
- Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution. (2014) (7)
- A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. (2019) (7)
- Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC). (2017) (7)
- Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. (2020) (7)
- Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. (2018) (7)
- Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome. (2020) (7)
- 1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI) (2020) (7)
- Can radiation-recall predict long lasting response to immune checkpoint inhibitors? (2020) (7)
- Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data. (2012) (7)
- OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy (2021) (7)
- MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO) (2017) (7)
- Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. (2018) (7)
- Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. (2021) (7)
- Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers. (2017) (7)
- Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. (2020) (7)
- CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers (2022) (7)
- Cannabis et cancer (2006) (7)
- Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review. (2022) (7)
- Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. (2016) (7)
- Recurrence of thymoma in the right atrium arising from the coronary sinus. (2013) (7)
- A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC (2021) (7)
- Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience. (2014) (6)
- Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (6)
- Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients (2018) (6)
- Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer. (2021) (6)
- IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer (2021) (6)
- Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. (2020) (6)
- Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients. (2013) (6)
- Lung Cancer Harboring Her2 Mutation: Epidemiological Characteristics and Therapeutic Perspectives (2012) (6)
- FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies (2021) (6)
- 1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins) (2020) (6)
- Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options (2016) (6)
- Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis (2018) (6)
- 1231PDA STUDY OF HSP90 INHIBITOR AT13387 ALONE AND IN COMBINATION WITH CRIZOTINIB (CZT) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (6)
- Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. (2018) (6)
- A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC). (2016) (6)
- 3025 Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT) (2015) (6)
- Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid EGFR/KRAS analysis in 43 cases. (2018) (6)
- MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy (2019) (6)
- Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. (2022) (6)
- Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) (2017) (6)
- Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer (2021) (6)
- ABT-869 in non-small cell lung cancer (NSCLC): Interim results. (2009) (6)
- MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC (2019) (6)
- Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease. (2022) (6)
- Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review (2021) (6)
- Thymic tumours: an update. (2013) (6)
- RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection. (2021) (6)
- Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. (2021) (6)
- Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. (2021) (6)
- [Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]. (2011) (5)
- 3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M (2015) (5)
- Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials (2013) (5)
- A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC) (2013) (5)
- Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. (2022) (5)
- OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study (2018) (5)
- [Second generation ALK inhibitors in non-small cell lung cancer: systemic review]. (2015) (5)
- P01.01 LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC (2021) (5)
- Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial). (2018) (5)
- Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial. (2018) (5)
- Liquid biopsies for residual disease and recurrence. (2021) (5)
- Targeting angiogenesis with oral agents. (2006) (5)
- Letter to the Editor about Sorich et al. (2019) (5)
- MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry (2018) (5)
- Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results. (2010) (5)
- Treatment duration of checkpoint inhibitors for NSCLC. (2019) (5)
- Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. (2020) (5)
- Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter? (2019) (5)
- An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON). (2018) (5)
- Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). (2012) (5)
- No need for contralateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors (2005) (5)
- A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). (2012) (5)
- MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC (2018) (5)
- MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion (2018) (5)
- Hepatic Intra-Arterial Chemotherapy with Immunotherapy in Non-Small Cell Lung Cancer. (2019) (5)
- [Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)]. (2011) (5)
- Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR (2019) (5)
- Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? (2015) (5)
- First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient. (2013) (4)
- [Nivolumab, a new hope in non-small cell lung cancer]. (2015) (4)
- Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (2017) (4)
- A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC). (2014) (4)
- A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS) (2008) (4)
- 3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC) (2015) (4)
- Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy (2020) (4)
- MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer (2019) (4)
- The Porto European Cancer Research Summit 2021 (2021) (4)
- 1164PPatterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression (2017) (4)
- Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors (2019) (4)
- Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer (2020) (4)
- MA09.11 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (2017) (4)
- Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. (2017) (4)
- Should surgery be part of the multimodality treatment for stage IIIB non‐small cell lung cancer? (2018) (4)
- Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung. (2017) (4)
- 112PPathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC) (2017) (4)
- Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor (2010) (4)
- [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]. (2007) (4)
- Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. (2022) (4)
- [Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]. (2012) (4)
- 3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (2019) (4)
- [3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance]. (2015) (4)
- Pathological central review of 290 thymic epithelial tumors (TET): The national network RYTHMIC experience. (2016) (4)
- Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients. (2016) (4)
- Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases. (2019) (4)
- PUL01.02 AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC (2021) (4)
- LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. (2022) (4)
- Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. (2020) (4)
- 27P Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC) (2022) (4)
- PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. (2021) (4)
- Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. (2020) (4)
- Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? (2014) (4)
- P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy (2018) (4)
- The efficacy of immune checkpoint inhibitors in thoracic malignancies (2021) (4)
- Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient. (2015) (4)
- Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. (2022) (4)
- Immunosenescence, inflammaging, and cancer immunotherapy efficacy (2022) (4)
- Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting (2021) (4)
- Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC (2019) (4)
- Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study. (2016) (3)
- Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants (2022) (3)
- Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) (2016) (3)
- Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. (2020) (3)
- Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study (2022) (3)
- Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. (2020) (3)
- Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. (2021) (3)
- Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study. (2021) (3)
- Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting (2019) (3)
- 100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial (2021) (3)
- Can MRI differentiate surrounding vertebral invasion from reactive inflammatory changes in superior sulcus tumor? (2021) (3)
- Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). (2013) (3)
- Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor. (2020) (3)
- 115P ORAL ETOPOSIDE IN PRETREATED ADVANCED THYMOMA AND THYMIC CARCINOMA. A FRENCH EXPERIENCE (2013) (3)
- 1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET) (2020) (3)
- Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. (2022) (3)
- Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. (2020) (3)
- [Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. (2011) (3)
- Thrombose et cancer bronchique. (2008) (3)
- P2.04-006 Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis: Topic: Thymic Malignancies Clinical and Translational (2017) (3)
- ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. (2019) (3)
- Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development program (phase I trials) at Institut Gustave Roussy. (2013) (3)
- Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176 (2021) (3)
- Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC). (2013) (3)
- Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital (2022) (3)
- ASSOCIATION OF LIPI SCORE WITH IMMUNOTHERAPY OUTCOMES IN ELDERLY POPULATION (2019) (3)
- Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy (2018) (3)
- Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients. (2022) (3)
- Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. (2017) (3)
- 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091 (2022) (3)
- Pharmacogenomics in NSCLC: mostly unsexy but desperately needed. (2014) (3)
- P87.02 AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC (2021) (3)
- Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. (2018) (3)
- 1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT) (2020) (3)
- MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer. (2016) (3)
- Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. (2022) (3)
- Pathological central review of 400 thymic epithelial tumors (TET): The national network RYTHMIC experience (2016) (3)
- [Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]. (2009) (3)
- Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations. (2013) (3)
- New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma. (2021) (3)
- 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations (2021) (3)
- P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients: Topic: IT Biomarkers (2017) (3)
- Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (2018) (3)
- Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. (2021) (3)
- Small cell lung cancer and other thoracic malignancies (2012) (3)
- 18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data (2020) (3)
- Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways. (2018) (3)
- Abstract 4581: Feasibility of an amplicon-based liquid biopsy forALKandROS1fusions in advanced non-small cell lung cancer (NSCLC) patients (2018) (3)
- EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer (2021) (3)
- Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC). (2009) (3)
- Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors (2021) (3)
- [KRAS status versus EGFR status in lung cancer therapy]. (2009) (3)
- OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study (2017) (3)
- Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort. (2020) (3)
- [Brain metastases of non small cell lung cancers: systemic treatments]. (2013) (3)
- Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network. (2020) (3)
- [Cannabis and cancer]. (2006) (3)
- MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC (2019) (3)
- The 5000% case: a glimpse into the financial issue of lung cancer treatment (2016) (3)
- [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]. (2012) (3)
- MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance (2019) (3)
- 1176PIDO-1 and PD-L1 predict response to immunotherapy in advanced non small cell lung cancer: An NGS and multiplex IHC analysis (2017) (3)
- First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50. (2021) (3)
- Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib (2021) (3)
- MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC) (2021) (2)
- P3.02b-102 Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients: Topic: EGFR RES (2017) (2)
- 1327PThe Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients (2017) (2)
- OA 03.01 Prevalence of Autoimmune Diseases in Thymic Epithelial Tumors (TET) Insights from RYTHMIC (2017) (2)
- Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts). (2019) (2)
- Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer (2022) (2)
- ANSELMA: ANtiangiogneic SEcond line Lung cancer Meta-Analysis in non-small cell lung cancer (NSCLC) (2016) (2)
- CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy? (2019) (2)
- Abstract 2597: Development and characterization of novel non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs)-derived xenograft (CDX) models (2018) (2)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer (2014) (2)
- MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers (2017) (2)
- Exploring the optimal use of alectinib. (2019) (2)
- Focus on Recommendations for the Management of Non-small Cell Lung Cancer (2019) (2)
- Toll like receptor 3 expression and efficacy of adjuvant treatment with polyadenylic-polyuridylic acid in patients with axillary node positive breast cancer: Results from two randomized trials. (2006) (2)
- Cannabis use and lung cancer: time to stop overlooking the problem? (2021) (2)
- Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis. (2021) (2)
- 50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results (2021) (2)
- Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations (2022) (2)
- Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases? (2020) (2)
- Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? (2017) (2)
- Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path) (2021) (2)
- Narrative review of immunotherapy in thymic malignancies (2021) (2)
- ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
- Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs). (2018) (2)
- Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC) (2020) (2)
- Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study (2019) (2)
- MA04.01 Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network (2021) (2)
- 143TiPSPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS (2015) (2)
- 9141 Volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC) (2009) (2)
- FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront. (2021) (2)
- P2-038: VEGFR1-2, C-Kit, HER2 and CD20 immunostaining in thymic epithelial tumors staged according to the WHO. (2007) (2)
- Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (2018) (2)
- Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study (2016) (2)
- A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer. (2015) (2)
- Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer (2021) (2)
- P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose (2019) (2)
- FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study (2021) (2)
- Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples (2016) (2)
- 467 Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01 (2015) (2)
- LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial (2022) (2)
- 2P Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours (2020) (2)
- Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model. (2018) (2)
- ERCC 1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy (2011) (2)
- [Lung cancer: an update in 2010]. (2010) (2)
- ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients (2019) (2)
- [Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]. (2020) (2)
- Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI). (2018) (2)
- Central nervous system metastases in thymic epithelial tumors: a brief report of real-world insight from RYTHMIC. (2021) (2)
- 3023 Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network (2015) (2)
- Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts). (2019) (2)
- 1309PEfficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) (2017) (2)
- Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance (2016) (2)
- An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves (2022) (2)
- The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (2019) (2)
- 1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center (2020) (2)
- Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply. (2020) (2)
- 386 Phase I study of the vascular disrupting agent (VDA) ombrabulin (Ob) in combination with taxanes (T) and platinum salts (PS) in patients (pts) with advanced solid tumors (2010) (2)
- PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT (2019) (2)
- The use of immunotherapy in older patients with advanced non-small cell lung cancer. (2022) (2)
- Multimodal Strategy may Improve Survival in Non-Small Cell Lung Cancer (NSCLC) Patients (PT) with Brain Metastases (BM) (2012) (2)
- 559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC) (2020) (2)
- ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
- An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients. (2018) (2)
- MA 02.02 Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC (2017) (2)
- Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC. (2020) (2)
- Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy. (2022) (1)
- [EGFR-targeted therapies: what's new?]. (2006) (1)
- 1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression (2020) (1)
- Abstract A51: Phase I, safety, tolerability and preliminary efficacy study of Tremelimumab (Trem) in combination with Gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM) (2015) (1)
- P1.05 Upfront Genomic Testing for Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Regimen: Preliminary Result of the Msn Study (2012) (1)
- A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment (2012) (1)
- Does Erythropoietin Promote Tumor Growth? (2008) (1)
- P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients (2018) (1)
- Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience (2021) (1)
- [Gemcitabine and non small-cell lung cancer]. (2007) (1)
- O1–131PHASE III STUDY OF CRIZOTINIB VS. CHEMOTHERAPY IN ADVANCED ALK+ NSCLC: PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (2013) (1)
- Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC. (2021) (1)
- Abstract B45: Upfront genomic testing in non-small cell lung cancer (NSCLC) patients: Preliminary result of the MSN study (2012) (1)
- Methodology of clinical trials in lung cancer. (2015) (1)
- P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: EGFR Clinical (2017) (1)
- P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (2018) (1)
- 53P Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC (2020) (1)
- MO01.10 Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge (2021) (1)
- Impact of tumor burden on tyrosine kinase inhibitors (TKI) efficacy in advanced non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations (EGFRm) and ALK rearrangement (ALK+). (2014) (1)
- 3076 Tumor control of advanced pulmonary carcinoid tumors with somatostatin analogs: Experience at Gustave Roussy (2015) (1)
- MA 05.03 The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC (2017) (1)
- 167TiP AdvanTIG-301: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC (2021) (1)
- Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report (2022) (1)
- MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients (2019) (1)
- Abstract 1867: Characterization of multiple driver alterations in acquired resistance to osimertinib inEGFR-mutated lung cancer: implementation of single cell approaches (2020) (1)
- OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC) (2022) (1)
- Abstract CT160: Safety of selpercatinib forRET-altered advanced solid tumors: a post hoc analysis of LIBRETTO-001 (2021) (1)
- 9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (2011) (1)
- [Role of immunotherapy in locally advanced non-small cell lung cancer]. (2020) (1)
- Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3–Positive Lymphatic/Vascular Endothelial Progenitor Cells (2009) (1)
- Late phase 1 studies: concepts and outcomes. (2021) (1)
- 1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC (2021) (1)
- Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better? (2021) (1)
- [Small cell lung cancer (CPC). Management of patients presenting with limited stage small cell carcinoma of the lung]. (2006) (1)
- Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy. (2017) (1)
- Challenges and controversies in thoracic oncology: a new ERJ series (2014) (1)
- 1331TiPPHASE I STUDY OF TREMELIMUMAB (TREM) IN COMBINATION WITH GEFITINIB (GEF) IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (EGFR-MUT) NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (1)
- Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy. (2005) (1)
- 1787P RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC (2021) (1)
- NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations (2022) (1)
- Association of LIPI score with immune checkpoint inhibitors (ICI) outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (pts). (2018) (1)
- Does Erythropoietin Promote Tumor Growth? Authors' reply (2008) (1)
- Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer (2021) (1)
- A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer (2020) (1)
- 3081 Molecular Tumor Board (MTB) in non-small cell lung cancers (NSCLC) to optimize targeted therapies: 4 years' experience at Gustave Roussy (2015) (1)
- 1742TiP RADIORYTHMIC: Phase III, opened, randomized study of post-operative radiotherapy (PORT) versus surveillance in stage IIb/III of Masaoka Koga thymoma after complete surgical resection (2021) (1)
- Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study. (2015) (1)
- MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders (2021) (1)
- 1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial (2020) (1)
- 1381TiPA randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial (2017) (1)
- Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001 (2020) (1)
- 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC (2011) (1)
- Immunotherapy in other thoracic malignancies and uncommon populations (2021) (1)
- Safety of lorlatinib in subgroups of patients from a phase I/II trial (2019) (1)
- Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic (2021) (1)
- Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy. (2020) (1)
- 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort (2020) (1)
- ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases (2020) (1)
- AB004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC (2017) (1)
- Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC) (2019) (1)
- Abstract 2147: Development of preclinical models to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies (2018) (1)
- MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer (2018) (1)
- Cystic brain metastases and RET fusion in lung cancer (2020) (1)
- Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer (2019) (1)
- P1.01-120 Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy (2019) (1)
- 184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer (2021) (1)
- RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. (2023) (1)
- OA15.05 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy (2022) (1)
- Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol (2019) (1)
- Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703. (2015) (1)
- C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC) (2007) (1)
- Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. (2022) (1)
- 1308PDPreliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC) (2017) (1)
- 34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions (2022) (1)
- Lorlatinib in ALK-or ROS 1-rearranged non-small cell lung cancer : an international , multicenter , open-label phase 1 trial (2018) (1)
- Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas (2019) (1)
- P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1: Topic: Phase III (2017) (1)
- Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. (2021) (1)
- Abstract B7: Assessing the clinical applications of ctDNA in patients with advanced stage metastatic cancer using our enhanced TAm-Seq platform (2015) (1)
- Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU) : Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey (2017) (1)
- What can be done for patients with NSCLC without druggable targets? (2013) (1)
- MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma (2019) (1)
- Caring for patients with cancer in the COVID-19 era (2020) (1)
- Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score (2022) (1)
- Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test (2022) (1)
- P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients (2018) (1)
- Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study. (2022) (1)
- Phase II Study of Bevacizumab in Combination with 1st-Line Chemotherapy or 2nd-Line Erlotinib in Non-Squamous Nsclc (Ns-Nsclc) Patients with Asymptomatic Untreated Brain Metastases (ML21823) (2012) (1)
- Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients. (2016) (1)
- Integrated molecular portrait of non-small cell lung cancers (2013) (1)
- HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients (2016) (1)
- [Molecular targeted therapies in small-cell lung cancer]. (2010) (1)
- 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994) (2020) (1)
- Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. (2011) (1)
- Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC). (2021) (1)
- [What is the best sequence of treatment for patients with EGFR mutations?]. (2011) (1)
- MA11.02 Mutational Burden in Pulmonary Neuroendocrine Tumors (puNETs) (2017) (1)
- Gemcitabine et cancer du sein. (2002) (1)
- [Management of targeted molecular therapies toxicities in thoracic cancerology]. (2008) (1)
- Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer (2022) (1)
- Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting. (2017) (1)
- Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) (2022) (1)
- EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. (2019) (1)
- [Gemcitabine and breast cancer]. (2002) (1)
- Multiple immune-related toxicities in cancer patients treated with anti-programmed death 1 immunotherapies: a new surrogate marker for clinical trials? (2021) (1)
- Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma (2023) (1)
- Abstract 1715: High ALK gene copy number as a predictor of response to crizotinib in non-small cell lung cancer cell lines (2012) (1)
- Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study (2017) (1)
- 1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC) (2021) (1)
- Perspectives on cancer care in older patients in France (2020) (1)
- [Managing nutritional support in thoracic oncology]. (2013) (1)
- Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial (2022) (1)
- 1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC) (2022) (1)
- Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study (2019) (1)
- Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial. (2022) (1)
- Preliminary results on mechanisms of resistance to ALK inhibitors: A prospective cohort from the MATCH-R study. (2018) (1)
- P62.01 PREVALUNG: Evaluation of Lung Cancer Prevalence in Patients With Smocking-associated Atherosclerotic Cardiovascular Diseases (2021) (1)
- A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC) (2016) (1)
- 1343PEfficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs (2017) (0)
- Gene expression profiling robustly predicts the outcome of patients diagnosed with early stage lung adenocarcinoma (2014) (0)
- P34.06 The Clinical Utility of Liquid Biopsy by Digital Droplet PCR in Patients with Advanced NSCLC (2021) (0)
- 9066 POSTER High ALK Gene Copy Number in Non-small Cell Advanced Lung Cancers (2011) (0)
- Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy. (2013) (0)
- AB008. Activated pathways of Thymic Epithelial Tumors: a RYTHMIC study (2022) (0)
- P3.03-27 Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population from the Ongoing Unicancer SAFIR02-Lung / IFCT-1301 Trial (2018) (0)
- 1629P Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network (2022) (0)
- P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients (2018) (0)
- Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study (2022) (0)
- PO-1246 Lung SBRT after pneumonectomy (2022) (0)
- Crystal structure of TrkA (G595R) kinase with repotrectinib (2021) (0)
- 22P Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC (2021) (0)
- Abstract 3414: Systematic comparison of ctDNA vs tissue sequencing with a large panel to guide therapy in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM) (2022) (0)
- 78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study (2022) (0)
- [Personalized medicine in oncology: from hope to reality]. (2012) (0)
- Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence. (2018) (0)
- 397OAntitumoral effect of low molecular weight heparin in localized lung cancer. A randomized phase III controlled trial (2017) (0)
- Contents Vol. 56,2012 (2012) (0)
- P2.01-07 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1-Containing Therapy (HUDSON) (2019) (0)
- MO4-7 Efficacy and safety with selpercatinib in patients with RET fusion+ NSCLC: Analysis by last prior systemic therapy (2021) (0)
- Adjuvant Chemotherapy Following Surgery for Lung Cancer (2008) (0)
- Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. (2023) (0)
- Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report (2010) (0)
- P2.01-038 Determinants of Frailty and Treatment Toxicity in Non-Small Cell Lung Cancer Patient (2017) (0)
- Weight, skeletal muscle mass, and adipose tissue loss during lung cancer patients' treatment. (2014) (0)
- OA03.08 Clinical Utility of CTDNA Driver Genomic Alterations (GA) Directing Targeted Therapy in Untreated Advanced NSCLC Patients (2019) (0)
- MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey (2019) (0)
- P2.03b-050 Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: Biomarkers (2017) (0)
- 18F-FDG PET–derived parameter total lesion glycolisis (TLG) as a tool to stratify patients (pts) with advanced non–small cell lung cancer (aNSCLC) treated with immunotherapy. (2022) (0)
- ErratumNonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint (2012) (0)
- 1090P HER2 copy number variation in non-small cell lung cancer (NSCLC) (2022) (0)
- Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies (2018) (0)
- Abstract 1114: Novel preclinical models of aggressive variants of castration-resistant prostate cancer (2020) (0)
- Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer (2019) (0)
- 47P Central nervous-system (CNS) metastases in thymic epithelial tumours (TET): Real-world insight from RYTHMIC (2021) (0)
- P1.09-17 CTNNB1 (Beta-Catenin) Mutations in Non-Small Cell Lung Carcinoma: A Clinicopathological Study of 18 Cases (2018) (0)
- Chapter 3 Systemic therapy for early-stage NSCLC (2011) (0)
- Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts). (2019) (0)
- 83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials (2021) (0)
- LincRNA-p21 as predictive response marker for preoperative chemoradiotherapy in rectal cancer. (2021) (0)
- Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer (2016) (0)
- P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (2019) (0)
- Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey (2022) (0)
- 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer (2021) (0)
- Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression. (2021) (0)
- Other Molecular Targeted Agents in Non-small Cell Lung Cancer (2010) (0)
- 1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge (2020) (0)
- Management and outcome of venous thromboembolic events (VTEs) during sunitinib treatment (2008) (0)
- Phase I / II study of neoadjuvant bevacizumab , erlotinib and 5-fl uorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer (2013) (0)
- [Thymic tumors]. (2017) (0)
- Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression. (2019) (0)
- Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. (2017) (0)
- 20P Human virome epitope-level antiviral antibody profiling identified the cytomegalovirus (CMV) as the main driver of senescent immune phenotype (SIP) in patients with advanced non-small cell lung cancer (aNSCLC) (2022) (0)
- National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France. (2014) (0)
- ORAL1.01: PHASE II TRIAL OF AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED THYMIC MALIG- NANCIES (2015) (0)
- Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. (2023) (0)
- Efficacy and Toxicity Observed in Malignant Pleural Mesothelioma Patients Treated in Phase I Trials at a Single Institution (2012) (0)
- [Bevacizumab and radiotherapy]. (2008) (0)
- 24IN MOLECULAR PATHOLOGY AND BIOLOGY IN EARLY NSCLC (2011) (0)
- Abstract 2357: Gene expression profiling robustly predicts the outcome of patients diagnosed with early stage lung adenocarcinoma (2014) (0)
- Multiple colic intussusceptions (2019) (0)
- PO-1255 Retrospective analysis of synchronous NSCLC stage IV oligometastatic treated with local treatments (2022) (0)
- Tumor-Specific CTL Different Antigenic Peptides by Peptide Transporter Lead to Recognition of Different Expression Levels of the TAP (2011) (0)
- [Neoadjuvant chemotherapy in non small cell lung cancer]. (2006) (0)
- Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC (2021) (0)
- CMAR_A_292730 2805..2810 (2021) (0)
- 1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy (2021) (0)
- 1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC) (2021) (0)
- A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs) (2019) (0)
- Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. (2023) (0)
- Abstract 358: A prospective study of prostate cancer metastases identifies an androgen receptor activity-low, stemness program associated with resistance to androgen receptor axis inhibitors and unveils mechanisms of clonal evolution (2021) (0)
- Crystal structure of TrkA kinase with repotrectinib (2021) (0)
- Oral 1.02. Sunitinib in patients with advanced thymic epithelial tumors (TET) (2015) (0)
- Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. (2019) (0)
- P2.04-007 Role of F-18-Choline Petscan in Recurrence of Thymic Epithelial Tumors (TET): Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- Abstract 2254: Variations in the epithelial-mesenchymal transition (EMT) program by non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) do not influence survival (2016) (0)
- Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial (2021) (0)
- EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront (2022) (0)
- Pan-tumor prognostic value of multiple immune protein expressions. (2019) (0)
- Abstract 1470: Detection of circulating tumor cells harboring a uniqueALKrearrangement inALK-positive non-small cell lung cancer. (2013) (0)
- 322MO Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2 (2022) (0)
- Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma (2023) (0)
- Outcomes of extended resection for locally advanced thymic malignancies. (2023) (0)
- 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC) (2015) (0)
- [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]. (2021) (0)
- P16.07 Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON) (2021) (0)
- 980P Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study (2022) (0)
- 9055 Outcome of non-small-cell lung cancer (NSCLC) patients treated for brain metastases (BM) in a single institution (2009) (0)
- 128IS SACRIFICING THE PHRENIC NERVE DURING THYMOMA RESECTION WORTHWHILE (2013) (0)
- Fast Facts: Non-Small-Cell Lung Cancer (2016) (0)
- Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. (2022) (0)
- FP07.11 Circulating Tumor DNA (ctDNA) Clearance as a Biomarker in Patients With Locally Advanced NSCLC Following Chemoradiation (2021) (0)
- Cancers bronchiques (2012) (0)
- Increased incidence of brain metastases in ERCC1-negative NSCLC patients treated with adjuvant cisplatin-based chemotherapy (2007) (0)
- OA18.07 Quality of Resection and Outcome in Stage III TETs: The French RYTHMIC Network Experience (2017) (0)
- The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer (2016) (0)
- [Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient]. (2007) (0)
- Author Correction: Caring for patients with cancer in the COVID-19 era (2020) (0)
- P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era (2021) (0)
- [Towards customized therapy for non small cell lung cancer]. (2008) (0)
- P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases (2018) (0)
- 42P Pleural effusion is a negative prognostic factor for immunotherapy in non small cell lung cancer (NSCLC): The PLUIE study (2020) (0)
- Concordance of plasmatic circulating DNA and matched metastatic tissue in metastatic urothelial carcinoma (2020) (0)
- Molecular testing in older patients treated for an advanced or metastatic nonsquamous non-small-cell lung cancer (2021) (0)
- Management of Extensive Small-Cell Lung Cancer (2006) (0)
- EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs (2022) (0)
- P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients (2021) (0)
- In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids. (2019) (0)
- MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC (2021) (0)
- Abstract 425: Characterization of TKI-induced drug-tolerant persister cells from a patient-derived cell line (2023) (0)
- Hyperprogressive disease during immunotherapy: an attempt to clarify different definitions (2019) (0)
- 9118 Effect of chemotherapy (CT) in patients (pts) with resected small-cell (SCLC) or large-cell neuro endocrine carcinoma (LCNEC) (2009) (0)
- OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study) (2017) (0)
- Subject Index Vol. 56,2012 (2012) (0)
- Natural language processing for patient selection in phase I/II oncology clinical trials (2021) (0)
- 1282P Biology of immune resistance in oncogenic driven advanced non-small cell lung cancer (aNSCLC) (2021) (0)
- Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer (2023) (0)
- FP05.04 Outcomes of Resected Thymic Epithelial Tumors (TET), insights from RYTHMIC (2021) (0)
- ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients. (2016) (0)
- Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1 (2019) (0)
- Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis. (2022) (0)
- Abstract 1951: Circulating tumor cell-derived explant models reveal DNA damage response-based therapeutic opportunities in non-small cell lung cancer (2022) (0)
- Differential epithelial and mesenchymal CTC profiling according to non-small cell lung cancer (NSCLC) molecular subtype. (2016) (0)
- Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib (2016) (0)
- P01.02 Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study (2021) (0)
- [Thrombosis and lung cancer]. (2008) (0)
- MATCH-R development of preclinical models from patient with acquired resistance to targeted therapy. (2018) (0)
- Abstract B043: Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance (2019) (0)
- Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. (2023) (0)
- 1290P Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC) (2020) (0)
- Genomic profile in pulmonary neuroendocrine tumors (puNETs): the whole-exome sequencing (WES) as a strategic tool (2016) (0)
- Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions (2023) (0)
- Comparative use of perioperative chemotherapy (CT) in non-small cell lung cancer (NSCLC) between 2004 and 2007. (2009) (0)
- Abstract 1929: Establishment, molecular and pharmacological profiling of novel prostate cancer-derived xenografts from patients with advanced, treatment-refractory, disease to identify resistance mechanisms and new therapeutic options (2019) (0)
- 1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy (2021) (0)
- Real-life experience of ceritinib in crizotinib-pretreatedadvanced non-small cell lung cancer patients (2019) (0)
- 1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC (2022) (0)
- Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer (2023) (0)
- MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (2018) (0)
- Crystal structure of TrkA (G595R) kinase domain (2021) (0)
- Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience (2019) (0)
- Assessment of clinical, radiological and radiomic predictive factors of bevacizumab efficacy in brain metastases radionecrosis treatment. (2018) (0)
- P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial (2018) (0)
- 3032A Activity and safety profile of lucitanib in patients with advanced thymic epithelial tumours (2015) (0)
- Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients. (2018) (0)
- P1.03-013 Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (2017) (0)
- CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non–small cell lung cancer (aNSCLC). (2022) (0)
- Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer (2019) (0)
- Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy. (2014) (0)
- Deciphering the metabolism/vascularization regional interlinks in primary NSCLC First-in human simultaneous full kinetic 18F-FDG PET-MRI voxel-wise analysis (2020) (0)
- Abstract 3016: Identification of the mechanisms of resistance to targeted therapies in advanced solid cancers (2021) (0)
- Quality of resection and outcome in stage III thymic epithelial tumors (TET): A retrospective analysis of 150 cases from the national network RYTHMIC experience (2016) (0)
- 284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC) (2021) (0)
- [Targeting of the AKT-mTOR pathway in head and neck and lung cancer]. (2009) (0)
- MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer (2021) (0)
- P2.07-060 Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIPI) for Immunotherapy in Advanced NSCLC Patients (2017) (0)
- Performant gene expression signatures predicting overall survival in resected stage I NSCLC have potential for translation in the clinic (2014) (0)
- 141PSelf-questionnaire to assess patient’s preferences for participation in phase I clinical trials (2018) (0)
- Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients (2016) (0)
- Novel mutations in sporadic typical carcinoids of the lung (lung-TC): Tumor genomic profile by next generation sequencing (NGS). (2016) (0)
- 9P Late phase I studies: Concepts and outcomes of a new clinical trial design (2021) (0)
- Method for semi-automated microscopy of filtration-enriched circulating tumor cells (2016) (0)
- Abstract 3413: Clinical utility of circulating tumor DNA sequencing with a large panel: The experience of Gustave Roussy/National Center for Precision Medicine (PRISM) (2022) (0)
- Management of Targeted Drug Resistance in NSCLC (2014) (0)
- 455 Pegasus Lung, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with non-small cell lung cancer (NSCLC) and mesothelioma (2021) (0)
- Circulating Endothelial Cells (CEC), Circulating Endothelial Progenitors (CEP) and Circulating Tumour Cells (CTC) as Markers for Response to Bevacizumab + Carboplatin/Paclitaxel (B+CP) or Bevacizumab/Erlotinib (B+E) in Advanced Non-squamous Non-small-cell Lung Cancer (ns-NSCLC) (2012) (0)
- 11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature (2021) (0)
- A Phase Ib Study to Evaluate the P13-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (2011) (0)
- P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON) (2018) (0)
- A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ) (2012) (0)
- EP-1250: Outcome after stereotactic radiotherapy for brain metastasis of lung cancer: a retrospective study (2016) (0)
- 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic (2021) (0)
- [Management of the cardiovascular complications of treatment in thoracic oncology]. (2014) (0)
- 1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC) (2022) (0)
- Abstract 598: Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling inBRAF-mutant non-small cell lung cancer (2021) (0)
- 1731P Lung cancer predisposition in Li-Fraumeni syndrome: Cohort from Gustave Roussy Institute (2022) (0)
- 135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer (2018) (0)
- P3.02c-031 Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT (2017) (0)
- Standards, Options and Recommendations (SOR) for the perioperative treatment of operable patients with resecable non small cell lung cancer (update) (2007) (0)
- Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104]. (2016) (0)
- P90.04 RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC (2021) (0)
- Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A) (2023) (0)
- 110P Prognostic and predictive value of lymphovascular invasion and lymph node status among breast cancer subtypes (2017) (0)
- P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol (2019) (0)
- 1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer (2022) (0)
- New Approaches to Cancer Care in a COVID-19 World—The Role of Health and Social Protection Policies (2021) (0)
- P1.08-009 Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer (2017) (0)
- Extrabronchial thoracic tumors: Their uniqueness calls for expertise (2014) (0)
- Abstract 2975: RAS precision medicine transatlantic partnership: Exploration of RAS and NF1 co-mutations in NSCLC (2022) (0)
- 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort (2020) (0)
- [The role of radiotherapy in the management of patients with small cell lung cancer]. (2007) (0)
- EP08.02-173 Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings (2022) (0)
- Abstract 1199: NSCLC KRAS G12C and G12V mutations drive different pathways and display specific drug sensitivity patterns. (2013) (0)
- P53.02 Integrated Profiling of Advanced Non-Small-Cell Lung Cancer: The EORTC IMMUcan Project - Lung Cohort (2021) (0)
- TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. (2023) (0)
- Abstract 1548: Baseline serum levels of osteopontin and thrombospondin-1 predict shorter overall survival in primary resected non-small cell lung cancer (2015) (0)
- Abstract PO-030: Outcome of older cancer patients infected with Covid19 at Gustave Roussy Cancer Center (2020) (0)
- Abstract 2230: Integrative genomic analysis of refractory metastatic cancer (2021) (0)
- 941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial (2022) (0)
- 3000 Chemo-radiation (CRT) and mutation profile in stage III Non Small Cell Lung Cancer (NSCLC): An analysis of the prognostic value (2015) (0)
- IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC. (2015) (0)
- Referee Acknowledgement for 2013 (2014) (0)
- OA18.01 Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort (2017) (0)
- Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay. (2018) (0)
- Occurrence of sarcopenia in patients with non-small cell lung cancer (NSCLC) treated with erlotinib with normal or increased body mass index (BMI). (2011) (0)
- P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale (2022) (0)
- Abstract 3113: Molecular and pharmacological profiling of a novel prostate cancer-derived xenograft panel to identify resistance mechanisms and new therapeutic options (2022) (0)
- 1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC) (2022) (0)
- [Angiogenesis targeting in lung cancers]. (2007) (0)
- Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial. (2022) (0)
- Abstract CT141: Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial) (2018) (0)
- 9013 Phase II results of ABT-869 treatment in patients with non small cell lung cancer (NSCLC) (2009) (0)
- 10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial (2023) (0)
- AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC. (2022) (0)
- Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301- SAFIR02-LUNG intergroup trial. (2021) (0)
- Assessment of efficacy and safety of bevacizumab in the treatment of brain metastases radionecrosis: A retrospective cohort analysis. (2018) (0)
- Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer (2022) (0)
- [Internet as a tool in oncology: critical analysis]. (2010) (0)
- 182P Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non-small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis (2018) (0)
- P84.01 The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients. (2021) (0)
- [Predicting response to Iressa: unexpected mechanism]. (2004) (0)
- F-FDG PET and DCE kinetic modeling and their interlinks in primary NSCLC: First-in human simultaneous [18F]FDG PET-MRI voxel-wise correlation analysis Running title: dynamic [18F]FDG PET/DCE-MRI interlinks in NSCLC (2020) (0)
- Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617) (2023) (0)
- 121P RAS precision medicine trans-atlantic partnership: Multicentre analysis of RAS and NF1 co-mutations in advanced NSCLC (2021) (0)
- P1.10-06 Pathological Characterization of Radon-Induced Lung Cancer in Rats (2019) (0)
- 366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial (2021) (0)
- MA07.07 Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA (2022) (0)
- P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT Biomarkers (2017) (0)
- Abstract A027: Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study. [R] (2023) (0)
- Abstract 4019: RET-MAP: An international multi-center study of patients with advanced non-small cell lung cancer and RET fusions (2022) (0)
- Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001 (0)
- Abstract 4818: Detection ofROS1rearrangement in circulating tumor cells in ROS1-positive non-small-cell lung cancer patients (2014) (0)
- L03.06 PHASE I TRIAL OF RAD001 (EVEROLIMUS) IN COMBINATION WITH RADIOTHERAPY IN NON-SMALL CELL LUNG CANCER (2013) (0)
- Abstract 4664: MatchR a preclinical platform of models resistant to innovative therapies (2023) (0)
- Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours (2018) (0)
- Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI). (2018) (0)
- 144PD Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors (2018) (0)
- Disseminated intravascular coagulation following administration of sunitinib. (2016) (0)
- 1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages (2021) (0)
- Abstract 3418: Alterations in PIK3CA/PTEN as resistance mechanisms in lung cancer patients progressing on first-line next generation EGFR/ALK tyrosine kinase inhibitors (2023) (0)
- 1371P Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): results from an EORTC pan-European survey. (2017) (0)
- 1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients (2021) (0)
- Abstract 595: Patterns and dynamics of genome instability drive metastatic activity in non-small cell lung cancer (NSCLC) circulating tumor cell (CTC)-derived xenograft (CDX) models (2021) (0)
- IS7. lung cancer (2012) (0)
- SP-0449 POSTOP RT/ CURRENT GUIDELINES AND MOVING POINTS (2012) (0)
- 1591P Whole exome sequencing: Evolution of indications and cost to inform public health policy decision-making (2020) (0)
- 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) (2021) (0)
- Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) (2022) (0)
- Detection of Circulating Tumour Cells in Peripheral Blood of Patients With Malignant Pleural Mesothelioma (2012) (0)
- 45IN INDIVIDUALISED THERAPY BASED ON TUMOR FEATURES (2009) (0)
- P2.04-003 Chemotherapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- To Continue or Not to Continue? That Is the Question. (2020) (0)
- PO-0779 Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey (2019) (0)
- 1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (2021) (0)
- OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study (2022) (0)
- 3130 Prognostic value of ALK gene copy number in advanced Non Small Cell Lung Cancer (NSCLC) patients (2015) (0)
- MA 11.01 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
- Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer (2007) (0)
- Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer. (2022) (0)
- Abstract 3654: Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis inALK-rearranged non-small-cell lung cancer (NSCLC) (2018) (0)
- Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. (2022) (0)
- Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer (2019) (0)
- P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors (2021) (0)
- 1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs) (2021) (0)
- Electrochemotherapy in radiotherapy-resistant epidural spinal cord compression in metastatic cancer patients. (2023) (0)
- Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
- Abstract 4678: Characterization of a PDX panel covering molecular diversity of non-small cell lung cancer to accelerate the development of precision therapy (2023) (0)
- [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]. (2015) (0)
- O-258 Bronchioloalveolar carcinoma and the EGFR pathway (2003) (0)
- Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. (2022) (0)
- Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence. (2020) (0)
- Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial. (2021) (0)
- P2.06-005 Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC: Topic: Phase I Trials (2017) (0)
- New windows open for immunotherapy in lung cancer (2018) (0)
- Abstract 2256: Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer (2016) (0)
- OA09.02 Should Surgery Be Part of the Multimodality Treatment for Stage IIIB Non-Small Cell Lung Cancer (2017) (0)
- IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC (2016) (0)
- Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. (2023) (0)
- Abstract 2122: Generation of a fully characterized preclinical PDX panel to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies (2019) (0)
- Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) (2016) (0)
- MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics (2021) (0)
- EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront (2022) (0)
- OA06.05 Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial (2017) (0)
- 169P Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): A retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling (2022) (0)
- [Lung cancer: is there a place for elective nodal irradiation?]. (2006) (0)
- De fi ning Synchronous Oligometastatic Non – Small Cell Lung Cancer: A Systematic Review (0)
- 18F-FDG PET and DCE kinetic modeling and their interlinks in primary NSCLC: First-in human simultaneous [18F]FDG PET-MRI voxel-wise correlation analysis (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Benjamin Besse?
Benjamin Besse is affiliated with the following schools:
